Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31648930 | 0.80 | ALDH1A1 (0.52) | ALDH1A1HTTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL18133119 | 0.79 | ALDH1A1 (0.57) | ALDH1A1HTTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL4404651 | 0.74 | KMT2A (0.52) | ALDH1A1HTTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL3897223 | 0.73 | ALDH1A1 (0.53) | ALDH1A1HTTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL23817280 | 0.72 | NPC1 (0.57) | ALDH1A1HTTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL2245329 | 0.72 | ALDH1A1 (0.47) | ALDH1A1HTTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL5451202 | 0.71 | ALDH1A1 (0.58) | ALDH1A1MEN1MAPTKMT2AGAA | |
| SCHEMBL11664862 | 0.70 | TAAR1 (0.49) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL15883199 | 0.70 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTKMT2ACYP1A2 | |
| SCHEMBL18171997 | 0.70 | ALDH1A1 (0.46) | ALDH1A1HTTSMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | GPR119, GOT2, IAPP | ALDH1A1 943/4885HTT 2240/4885SMN1; SMN2 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.